AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01443195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron preparation
Description: Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation).
Study NCT02653664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsychoEducation
Description: Condition #1
Study NCT02653664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Hypnosis Training
Description: Condition #2
Study NCT02653664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Condition #3
Study NCT04005638 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT04005638 — intervention group
Intervention type: BIOLOGICAL
Intervention: urine sample
Description: 12 ml
Study NCT00848536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution
Description: One drop once daily in the evening for 3 months
Study NCT00848536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
Description: One drop once daily in the evening for 3 months
Study NCT02435160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (T) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and trastuzumab maintenance therapy
Description: * bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Study NCT00365365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance therapy
Description: - bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Study NCT02511535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE booster vaccination
Study NCT02511535 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE booster vaccination
Study NCT04343794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOVITALS
Description: Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
Study NCT02942563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.
Study NCT02267187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
Study NCT02267187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
Study NCT02267187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coleman Cannulas
Description: The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
Study NCT02267187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tefla non-adherent gauze pad
Description: The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
Study NCT01609387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fit For me
Study NCT04050709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK Suspension for Infusion
Study NCT01522495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging
Description: SPY Imaging to assess tissue perfusion
Study NCT01609387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Davitamon
Study NCT01746875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
Study NCT01746875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
Study NCT01118091 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
Study NCT01118091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 enriched Young TIL
Description: Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
Study NCT01542099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml.
Study NCT01542099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml.
Study NCT01458145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding the Baby Home Visiting Program
Description: Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
Study NCT02096536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: vancomycin administration based on decision of treating physician
Study NCT00816270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Upper eyelid blepharoplasty
Description: Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
Study NCT00704834 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: 35 cc of peripheral blood will be obtained by venipuncture from each subject.
Study NCT01015443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
Study NCT01015443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
Study NCT01015443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
Study NCT01877954 — intervention group
Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane beclometasone dipropionate
Study NCT01877954 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate
Study NCT03017287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMe App
Description: Assessment of the the GlucoMe App
Study NCT01708525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01708525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Water
Description: A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
Study NCT02579733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study NCT02579733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01260389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care intervention
Description: Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
Study NCT04263506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vignette with emphasis on supervisor's opinion
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
Study NCT04263506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vignette with emphasis on supervisor's opinion
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
Study NCT04163991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for IV infusion
Study NCT04163991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline for IV infusion
Study NCT01015443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
Study NCT01015443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
Study NCT01015443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
Study NCT03887832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMBI digital app
Description: Digital platform on the smartphone for the media package
Study NCT03887832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media package
Description: The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
Study NCT03887832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard newborn and infant care
Description: Recommended standard pediatric primary care will be provided for infants up to 6 months.
Study NCT03887832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard newborn and infant care
Description: Recommended standard pediatric primary care will be provided for infants up to 6 months.
Study NCT03790735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FISH
Description: Targeted chromosomal aberrations detection
Study NCT00796783 — intervention group
Intervention type: DRUG
Intervention: Cushing's syndrome confirmation
Study NCT02464319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: 1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
Study NCT02464319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: 1 million U doses of placebo s.c. injection active group: placebo group =1:1
Study NCT03339427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: different doses of vitamin D supplementation
Study NCT03339427 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: control group
Study NCT01900548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein (HPHL)
Description: The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
Study NCT01900548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein (HPLL)
Description: The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
Study NCT01900548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (P)
Description: Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
Study NCT01900548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
Study NCT01446653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus feedback
Description: Provides an MI + feedback intervention supplemented with video and brochures-based information
Study NCT01446653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video arm will provide information via documentary video
Study NCT01446653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Brochure
Description: Informational Brochures are given to participants following baseline assessment.
Study NCT03849989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage.
Study NCT02337946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT02337946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Study NCT00350506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Study NCT01421901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem i.v,m 1g, once a day, 3 days
Study NCT04692051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Cisplatin
Description: Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
Study NCT04692051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
Study NCT02988960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous
Study NCT01900548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
Study NCT03020186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity
Study NCT03020186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity+ MED diet
Study NCT02988960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intratumoral